Evidence map›Paper›PMID 30426393›Full record

ArticleNeurotoxicity research2019

Low Molecular Weight Sulfated Chitosan: Neuroprotective Effect on Rotenone-Induced In Vitro Parkinson's Disease.

Venkatesan Manigandan, Jagatheesan Nataraj, Ramachandran Karthik, Thamilarasan Manivasagam, Ramachandran Saravanan, Arokyasamy Justin Thenmozhi, Musthafa Mohamed Essa, Gilles J Guillemin

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Antioxidant Therapeutic Strategies in Neurodegenerative Diseases.International journal of molecular sciences · 2022
    Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Venkatesan ManigandanNative Medicine and Marine Pharmacology Laboratory, Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education, Kelambakkam, Chennai, Tamil Nadu, 603 103, India.
Jagatheesan NatarajDepartment of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, Tamil Nadu, 608 002, India.
Ramachandran KarthikNative Medicine and Marine Pharmacology Laboratory, Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education, Kelambakkam, Chennai, Tamil Nadu, 603 103, India.
Thamilarasan ManivasagamDepartment of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, Tamil Nadu, 608 002, India.
Ramachandran SaravananNative Medicine and Marine Pharmacology Laboratory, Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education, Kelambakkam, Chennai, Tamil Nadu, 603 103, India. saranprp@gmail.com.ORCID http://orcid.org/0000-0003-0044-4472
Arokyasamy Justin ThenmozhiDepartment of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, Tamil Nadu, 608 002, India.
Musthafa Mohamed EssaDepartment of Food Science and Nutrition, CAMS, Sultan Qaboos University, Muscat, Oman.
Gilles J GuilleminNeuropharmacology Group, MND and Neurodegenerative Diseases Research Centre, Australian School of Advanced Medicine, Macquarie University, Balaclava Road, North Ryde, Sydney, NSW, 2109, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present investigation was an attempt to study the effect of low molecular weight sulfated chitosan (LMWSC) on in vitro rotenone model of Parkinson's disease (PD) by evaluating cell viability, oxidative stress, mitochondrial membrane potential, DNA fragmentation, and apoptosis. Incubation of SH-SY5Y cells with 100 nm rotenone resulted in neuronal cell death, redox imbalanced mitochondrial dysfunction, DNA fragmentation, condensation, and apoptotic cellular morphology. Rotenone exposure enhanced the expression of preapoptotic (cytochrome C (cyto c), caspase-3, -8, -9, and Bax) and down-regulated the expression of anti-apoptotic (Bcl-2) markers. Reduction of the intracellular reactive oxygen species (ROS) levels ensued due to pretreatment of LMWSC along with consequent normalization of antioxidant enzymes, mitigation of rotenone induced mitochondrial dysfunction and apoptosis. Our current findings suggested that LMWSC exhibit the pronounced neuroprotective effects, which could be due to its antioxidant, mitochondrial protection, and anti-apoptotic properties. We thus conclude that LMWSC could be developed as a novel therapeutic molecule for the benefit of reducing the consequences of PD. However, further extensive preclinical and clinical studies are warranted.

Indexed as

Antiparkinson AgentsApoptosisCell Line, TumorCell SurvivalChitosanDNA FragmentationDose-Response Relationship, DrugHumansMembrane Potential, MitochondrialNeuronsNeuroprotective AgentsOxidative StressParkinsonian DisordersReactive Oxygen SpeciesRotenoneAntiparkinson AgentsChitosanNeuroprotective AgentsReactive Oxygen SpeciesRotenoneApoptosisMitochondrial dysfunctionNeuronal damageOxidative stressRotenoneSulfated chitosan

Identifiers

PMID30426393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.